Supplementary materials

Table S1: The risks of complications in each year based on the UKPDS study

|  |  |  |  |
| --- | --- | --- | --- |
| Complication | Year 1 | Year 2 | Year 3 |
| Myocardial infarction | 0.00251624 | 0.006039183 | 0.010460302 |
| Stroke | 0.000344524 | 0.000979429 | 0.001890693 |
| End state renal disease | 0.00003840 | 0.000148239 | 0.000329386 |
| Blindness | 0.00116719 | 0.002395258 | 0.0039201 |
| Amputation | 0.000116346 | 0.000280568 | 0.000544055 |

*Note*: UKPDS study: the United Kingdom Prospective Diabetes Study

Table S2: The market share of biphasic human insulin 30

|  |  |  |  |
| --- | --- | --- | --- |
|  | Year 1 | Year 2 | Year 3 |
| BIAsp 30 | 1.24% | 2.48% | 3.72% |
| BHI 30 | 98.76% | 97.52% | 96.28% |

*Note*: BIAsp 30: Biphasic Insulin Aspart 30; BHI 30: Biphasic Human Insulin 30